News about "Antibody-Drug Conjugate "

Glenmark Advances Global Phase 3 Trial of HER2-Targeted ADC for Platinum-Resistant Ovarian Cancer

Glenmark Specialty has initiated patient enrolment in India for the Phase 3 trial of trastuzumab rezetecan, aiming to expand treatment options for patients with platinum-resistant ovarian cancer across its licensed global markets.

Antibody-Drug Conjugate | 04/07/2026 | By News Bureau

European Commission Approves Gilead's Trodelvy as First-Line Treatment for Metastatic Triple-Negative Breast Cancer

The European Commission has approved Trodelvy for first-line treatment of unresectable or metastatic triple-negative breast cancer, offering a new therapeutic option for patients with one of the most aggressive forms of breast cancer.

Antibody-Drug Conjugate | 25/06/2026 | By News Bureau

Zai Lab Secures China Approval for TIVDAK

Zai Lab has received China NMPA approval for TIVDAK (tisotumab vedotin), the first Antibody-Drug Conjugate (ADC) approved for previously treated recurrent or metastatic cervical cancer in China. The approval is supported by phase 3 innovaTV 301 trial data demonstrating a statistically significant overall survival benefit.

Antibody Drug Conjugate | 09/06/2026 | By News Bureau

Antengene Corporation receives CDE endorsement to begin pivotal phase 3 CLINCH-3 study of ATG-022

Antengene has received approval from China’s Center for Drug Evaluation to initiate the pivotal Phase 3 CLINCH-3 study of ATG-022, advancing the development of its innovative antibody-drug conjugate for CLDN18.2-positive gastric cancers.

Antibody-Drug Conjugate | 30/05/2026 | By News Bureau

US FDA Approves DECNUPAZ for Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

AbbVie has received US FDA approval for DECNUPAZ to treat adults with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), marking the first and only outpatient-initiated ADC for BPDCN and AbbVie’s first approved Antibody Drug Conjugate (ADC) for hematologic malignancies.

Antibody Drug Conjugate | 30/05/2026 | By News Bureau

Pfizer and Innovent Biologics Partner to Advance Global Oncology Drug Development

Pfizer and Innovent Biologics have entered a global strategic collaboration to develop innovative oncology medicines, combining 12 discovery and early-stage programs to accelerate cancer drug development through shared research, clinical development, and commercialisation efforts.

Antibody Drug Conjugate | 29/05/2026 | By News Bureau |  112

Emiltatug Ledadotin Wins FDA Breakthrough Tag for Adenoid Cystic Carcinoma

Emiltatug Ledadotin receives U.S. Food and Drug Administration Breakthrough Therapy designation for adenoid cystic carcinoma, a potentially innovative and differentiated Antibody Drug Conjugate (ADC) directed against B7-H4, a well-characterised target in certain cancers including ACC.

Antibody Drug Conjugate | 13/05/2026 | By News Bureau |  135

GSK plc Secures China Approval for Blenrep Combination Therapy in Multiple Myelom

National Medical Products Administration approves Blenrep with bortezomib and dexamethasone for relapsed or refractory patients, backed by strong phase III trial outcomes.

Antibody-Drug Conjugate | 21/04/2026 | By News Bureau |  108

GlycoNex Secures PMDA Nod for First-in-Human Trial of Cancer Drug GNX1021

Japan’s Pharmaceuticals and Medical Devices Agency approves Phase I clinical trial of GlycoNex’s novel antibody-drug conjugate targeting gastrointestinal cancers.

Antibody-drug Conjugate | 16/04/2026 | By News Bureau |  224

PMDA Expands Use of Enhertu for Second-Line Gastric Cancer in Japan

Regulatory update allows Enhertu to be used earlier in treatment for HER2-positive advanced gastric cancer, backed by phase III data showing improved survival outcomes.

Antibody-drug Conjugate | 25/03/2026 | By News Bureau |  278